Leerink Partnrs Lowers Earnings Estimates for NeoGenomics

NeoGenomics, Inc. (NASDAQ:NEO) – Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of NeoGenomics in a research note issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the medical research company will earn ($0.07) per share for the quarter, down from their prior estimate of ($0.02). The consensus estimate for NeoGenomics’ current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for NeoGenomics’ Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.10) EPS and FY2026 earnings at $0.07 EPS.

A number of other brokerages also recently weighed in on NEO. Jefferies Financial Group began coverage on NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price on the stock. Bank of America upped their price objective on shares of NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC reissued a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research note on Friday, January 10th. Finally, Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.30.

NeoGenomics Stock Performance

Shares of NASDAQ:NEO opened at $14.50 on Thursday. NeoGenomics has a 52 week low of $12.13 and a 52 week high of $19.11. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.91 and a current ratio of 1.99. The firm has a 50 day simple moving average of $16.60 and a 200 day simple moving average of $15.69.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm had revenue of $167.80 million for the quarter, compared to analysts’ expectations of $167.00 million. During the same quarter last year, the business posted ($0.06) EPS. NeoGenomics’s revenue was up 10.5% on a year-over-year basis.

Insider Buying and Selling at NeoGenomics

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares in the company, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Nordea Investment Management AB boosted its position in shares of NeoGenomics by 2.8% in the fourth quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company’s stock valued at $1,301,000 after acquiring an additional 2,125 shares during the period. Geode Capital Management LLC raised its stake in NeoGenomics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock valued at $45,022,000 after purchasing an additional 36,136 shares during the last quarter. Jennison Associates LLC boosted its holdings in NeoGenomics by 4.7% in the 3rd quarter. Jennison Associates LLC now owns 1,276,468 shares of the medical research company’s stock valued at $18,828,000 after purchasing an additional 57,041 shares during the period. Blue Trust Inc. grew its position in NeoGenomics by 42.3% in the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after purchasing an additional 987 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in shares of NeoGenomics by 152.6% during the 2nd quarter. Sei Investments Co. now owns 263,761 shares of the medical research company’s stock worth $3,658,000 after purchasing an additional 159,350 shares during the period. Institutional investors own 98.50% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.